In this article, we will discuss Olaparib (Clinical Trials Experience-8). So, let’s get started.
Treatment of gBRCAm HER2-negative Metastatic Breast Cancer
OlympiAD
The safety of Lynparza tablets as monotherapy was also evaluated in gBRCAm patients with HER2-negative metastatic breast cancer who had previously received up to two lines of chemotherapy for the
treatment of metastatic disease in OlympiAD. This study was a randomized, open-label, multi-center study in which 296 patients received either Lynparza 300 mg twice daily (n=205) or a chemotherapy (capecitabine, eribulin, or vinorelbine) of the healthcare provider’s choice (n=91) until disease progression or unacceptable toxicity.